MBI Researcher Highlight: Dr. Paramita Chakrabarty
Dr. Paramita Chakrabarty’s research investigates the role of neuroinflammation in Alzheimer’s disease.
Dr. Paramita Chakrabarty’s research investigates the role of neuroinflammation in Alzheimer’s disease.
The McKnight Brain Institute’s signature programs in neurological diseases include ALS, Alzheimer’s disease, brain tumor immunotherapy, and Parkinson’s disease, as well as other neurodegenerative disorders. The MBI is dedicated to accelerating discoveries in these fields to enhance brain health and develop innovative therapies. 1Florida Alzheimer’s Disease Research Center (1Florida…
The McKnight Brain Institute’s signature programs in cognition, behavior, and sensation include age-related cognitive decline, developmental disorders, pain, sensory dysfunction, and substance use disorders and other neuropsychiatric diseases. The MBI is dedicated to accelerating discoveries to enhance brain health and develop innovative therapies. Center for Addiction Research & Education…
The McKnight Brain Institute’s signature programs in acquired neural injury include neural control of respiration, spinal cord injury, stroke, and traumatic brain injury. The MBI is dedicated to accelerating discoveries to enhance brain health and develop innovative therapies. Brain Injury, Rehabilitation, and Neuroresilience Center (BRAIN) BRAIN Center…
Under new grant, a research team co-led by Dr. Malú Gámez Tansey will investigate possible links between the immune system and neurodegeneration in frontotemporal dementia.
The Harry T. Mangurian Jr. Foundation supported grants for two Lewy body dementia pilot studies.
Dr. Malú Tansey discusses new role as journal’s editor-in-chief, career path and research focus.
Neuroimmunologist Dr. Malú Tansey is highlighted in Knowable Magazine.
UF is collaborating on clinical trial testing if high-intensity treadmill exercise is effective in decreasing signs of Parkinson’s.
New study lends insights into factors that could help predict the efficacy of gene therapies using a genetically engineered antibody to target abnormal tau proteins.